10x Genomics price target lowered to $12 from $14 at JPMorgan
JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...
GEN21d
After a Year of Launches, 10x Refocuses on Customer Support, Biopharma Market Growth
CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales reorganization and grow base of industry users.